| dc.creator |
Ikizler, Talat Alp |
|
| dc.creator |
Elsurer Afsar, Rengin |
|
| dc.creator |
Afsar, Baris |
|
| dc.date |
2023-07-01T00:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:23:51Z |
|
| dc.date.available |
2025-02-25T10:23:51Z |
|
| dc.identifier |
6c2b88db-5f25-4189-9cac-e6b59fa49f45 |
|
| dc.identifier |
10.1016/j.ekir.2023.04.027 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/6c2b88db-5f25-4189-9cac-e6b59fa49f45/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/100066 |
|
| dc.description |
Protein energy wasting (PEW), mostly characterized by decreased body stores of protein and energy sources, particularly in the skeletal muscle compartment, is highly prevalent in patients with moderate to advanced chronic kidney disease (CKD). Fibroblast growth factor 23 (FGF23) is an endocrine hormone secreted from bone and has systemic actions on skeletal muscle. In CKD, FGF23 is elevated and its coreceptor α-klotho is suppressed. Multiple lines of evidence suggest that FGF23 is interconnected with various mechanisms of skeletal muscle wasting in CKD, including systemic and local inflammation, exaggerated oxidative stress, insulin resistance (IR), and abnormalities in adipocytokine metabolism. Investigation of metabolic actions of FGF23 on muscle tissue could provide new insights into metabolic and nutritional abnormalities observed in patients with CKD. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Fibroblast Growth Factor 23 and Muscle Wasting: A Metabolic Point of View |
|
| dc.type |
info:eu-repo/semantics/article |
|